Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 6Anxiety Disorders 4Breast Neoplasms 3Motor Activity 2Fatigue 2Depression 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Sleep Initiation and Maintenance Disorders 1Prostatic Neoplasms 1Parasomnias 1Pain 1Ovarian Neoplasms 1Muscle Weakness 1Multiple Endocrine Neoplasia Type 1 1Leukemia 1Head and Neck Neoplasms 1Caregiver Burden 1Cancer Pain 1

Interventions

Fulvestrant 5Exercise 5Eating 5Standard of Care 3Sodium Chloride 3Diet 3Alpelisib 3ribociclib 2gallium Ga 68 dotatate 2exemestane 2Vitamin D 2Tamoxifen 2Magnetic Resonance Spectroscopy 2Letrozole 2Ethanol 2Blood Specimen Collection 2Anastrozole 2zopiclone 1ziprasidone 1veliparib 1testosterone undecanoate 1testosterone enanthate 1pazopanib 1mirabegron 1methyl hydroxyethyl cellulose 1lenvatinib 1fluorocholine 1evolocumab 1dimethandrolone-undecanoate 1cyclopropapyrroloindole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 1 × Autogenic Training × Clear all
NCT02873559 2024-05-29

PROGRESS

University Hospital, Gentofte, Copenhagen

Phase 2/3 Completed
192 enrolled
Endocrine

Motor Activity, Multiple Endocrine Neoplasia Type 1, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡